Directly observed therapy programmes for anti-retroviral treatment amongst injection drug users in Vancouver: Access, adherence and outcomes

International Journal of Drug Policy

Volumn 18, Issue 4, 2007, Pages 281-287

  Tyndall, Mark W ^a   McNally, Maggi ^a   Lai, Calvin ^a   Zhang, Ruth ^a   Wood, Evan ^a   Kerr, Thomas ^a   Montaner, Julio G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Anti retrovirals; Directly observed therapy; HIV AIDS; Injection drug use

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANADA; CD4 LYMPHOCYTE COUNT; CELL COUNT; COMORBIDITY; DIRECTLY OBSERVED THERAPY; DRUG DEPENDENCE; DRUG WITHDRAWAL; ETHNICITY; EVALUATION; FEMALE; FOLLOW UP; HEALTH CARE ACCESS; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTING DRUG USER; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OUTPATIENT DEPARTMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRAL LOAD SUPPRESSION; VIRUS LOAD;

ADULT; AGED; ANTI-HIV AGENTS; BRITISH COLUMBIA; CD4 LYMPHOCYTE COUNT; DIRECTLY OBSERVED THERAPY; EFFICIENCY, ORGANIZATIONAL; FEMALE; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 34547224624     PISSN: 09553959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugpo.2006.11.009     Document Type: Article

References (45)

1. Aceijas C., Oppenheimer E., Stimson G.V., Ashcroft R.E., Matic S., and Hickman M. Anti-retroviral treatment for injecting drug users in developing and transitional countries 1 year before the end of the "Treating 3 million by 2005. Making it happen. The WHO strategy" ("3 by 5"). Addiction 101 (2006) 1246-1253
2. Altice F.L., Mezger J.A., Hodges J., Bruce R.D., Marinovich A., Walton M., et al. Developing a directly administered anti-retroviral therapy intervention for HIV-infected drug users: Implications for program replication. Clinical Infectious Diseases 38 Suppl. 5 (2004) S376-S387
3. Arnsten J.H., Demas P.A., Grant R.W., Gourevitch M.N., Farzadegan H., Howard A.A., et al. Impact of active drug use on anti-retroviral therapy adherence and viral suppression in HIV-infected drug users. Journal of General Internal Medicine 17 (2002) 377-381
4. Bangsberg D.R. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clinical Infectious Diseases 43 (2006) 939-941
5. Bangsberg D.R., Charlebois E.D., Grant R.M., Holodniy M., Deeks S.G., Perry S., et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 17 (2003) 1925-1932
6. Bangsberg D.R., Mundy L.M., and Tulsky J.P. Expanding directly observed therapy: Tuberculosis to human immunodeficiency virus. American Journal of Medicine 110 (2001) 664-666
7. Carrieri M.P., Chesney M.A., Spire B., Loundou A., Sobel A., Lepeu G., et al. Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users. International Journal of Behavioural Medicine 10 (2003) 1-14
8. Cohen D.A., Wu S.Y., and Farley T.A. Comparing the cost-effectiveness of HIV prevention interventions. Journal of Acquired Immune Deficiency Syndrome 37 (2004) 1404-1414
9. Conway B., Prasad J., Reynolds R., Farley J., Jones M., Jutha S., et al. Directly observed therapy for the management of HIV-infected patients in a methadone program. Clinical Infectious Diseases 38 Suppl. 5 (2004) S402-S408
10. Craib K.J., Spittal P.M., Wood E., Laliberte N., Hogg R.S., Li K., et al. Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. CMAJ 168 (2003) 19-24
11. Ding L., Landon B.E., Wilson I.B., Wong M.D., Shapiro M.F., and Cleary P.D. Predictors and consequences of negative physician attitudes toward HIV-infected injection drug users. Archives of Internal Medicine 165 (2005) 618-623
12. Dronda F., Zamora J., Moreno S., Moreno A., Casado J.L., Muriel A., et al. CD4 cell recovery during successful anti-retroviral therapy in naive HIV-infected patients: The role of intravenous drug use. AIDS 18 (2004) 2210-2212
13. Gross R., Yip B., Re III V.L., Wood E., Alexander C.S., Harrigan P.R., et al. A simple, dynamic measure of anti-retroviral therapy adherence predicts failure to maintain HIV-1 suppression. The Journal of Infectious Diseases 194 (2006) 1108-1114
14. Hammer S.M., Saag M.S., Schechter M., Montaner J.S., Schooley R.T., Jacobsen D.M., et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 296 (2006) 827-843
15. Harrigan P.R., Hogg R.S., Dong W.W., Yip B., Wynhoven B., Woodward J., et al. Predictors of HIV drug-resistance mutations in a large anti-retroviral-naive cohort initiating triple anti-retroviral therapy. The Journal of Infectious Diseases 191 (2005) 339-347
16. Hogg R.S., Yip B., Kully C., Craib K.J., O'Shaughnessy M.V., Schechter M.T., et al. Improved survival among HIV-infected patients after initiation of triple-drug anti-retroviral regimens [see comments]. CMAJ 160 (1999) 659-665
17. Howard A.A., Arnsten J.H., Lo Y., Vlahov D., Rich J.D., Schuman P., et al. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS 16 (2002) 2175-2182
18. Knowlton A., Arnsten J., Eldred L., Wilkinson J., Gourevitch M., Shade S., et al. Individual, interpersonal, and structural correlates of effective HAART use among urban active injection drug users. Journal of Acquired Immune Deficiency Syndrome 41 (2006) 486-492
19. Kohli R., Lo Y., Howard A.A., Buono D., Floris-Moore M., Klein R.S., et al. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active anti-retroviral therapy. Clinical Infectious Diseases 41 (2005) 864-872
20. Loughlin A., Metsch L., Gardner L., Anderson-Mahoney P., Barrigan M., and Strathdee S. Provider barriers to prescribing HAART to medically-eligible HIV-infected drug users. AIDS Care 16 (2004) 485-500
21. Lucas G.M., Flexner C.W., and Moore R.D. Directly administered anti-retroviral therapy in the treatment of HIV infection: Benefit or burden?. AIDS Patient Care STDS 16 (2002) 527-535
22. McCance-Katz E.F., Gourevitch M.N., Arnsten J., Sarlo J., Rainey P., and Jatlow P. Modified directly observed therapy (MDOT) for injection drug users with HIV disease. The American Journal of Addictions 11 (2002) 271-278
23. Moss A.R., Hahn J.A., Perry S., Charlebois E.D., Guzman D., Clark R.A., et al. Adherence to highly active anti-retroviral therapy in the homeless population in San Francisco: A prospective study. Clinical Infectious Diseases 39 (2004) 1190-1198
24. Palepu A., Tyndall M.W., Joy R., Kerr T., Wood E., Press N., et al. Anti-retroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: The role of methadone maintenance therapy. Drug and Alcohol Dependence (2006)
25. Palepu A., Tyndall M., Yip B., O'Shaughnessy M.V., Hogg R.S., Schechter M.T., et al. Impaired virologic response to highly active anti-retroviral therapy associated with ongoing injection drug use. Journal of Acquired Immune Deficiency Syndrome 32 (2003) 522-526
26. Porter K., Babiker A., Bhaskaran K., Darbyshire J., Pezzotti P., et al. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 362 (2003) 1267-1274
27. Rhodes T., Ball A., Stimson G.V., Kobyshcha Y., Fitch C., Pokrovsky V., et al. HIV infection associated with drug injecting in the newly independent states, eastern Europe: The social and economic context of epidemics. Addiction 94 (1999) 1323-1336
28. Sambamoorthi U., Warner L.A., Crystal S., and Walkup J. Drug abuse, methadone treatment, and health services use among injection drug users with AIDS. Drug and Alcohol Dependence 60 (2000) 77-89
29. Santos C.Q., Adeyemi O., and Tenorio A.R. Attitudes toward directly administered anti-retroviral therapy (DAART) among HIV-positive inpatients in an inner city public hospital. AIDS Care 18 (2006) 808-811
30. Shannon K., Bright V., Duddy J., and Tyndall M.W. Access and utilization of HIV treatment and services among women sex workers in Vancouver's Downtown Eastside. Journal of Urban Health 82 (2005) 488-497
31. Solomon L., Stein M., Flynn C., Schuman P., Schoenbaum E., Moore J., et al. Health services use by urban women with or at risk for HIV-1 infection: The HIV Epidemiology Research Study (HERS). Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 17 (1998) 253-261
32. Spittal P.M., Craib K.J., Wood E., Laliberte N., Li K., Tyndall M.W., et al. Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver. CMAJ 166 (2002) 894-899
33. Strathdee S.A., Palepu A., Cornelisse P.G., Yip B., O'Shaughnessy M.V., Montaner J.S., et al. Barriers to use of free anti-retroviral therapy in injection drug users [see comments]. JAMA 280 (1998) 547-549
34. Strathdee S.A., Patrick D.M., Currie S.L., Cornelisse P.G., Rekart M.L., Montaner J.S., et al. Needle exchange is not enough: Lessons from the Vancouver injecting drug use study. AIDS 11 (1997) F59-F65
35. Strathdee S.A., van Ameijden E.J., Mesquita F., Wodak A., Rana S., and Vlahov D. Can HIV epidemics among injection drug users be prevented?. AIDS 12 (1998) S71-S79
36. Tyndall M.W., Currie S., Spittal P., Li K., Wood E., O'Shaughnessy M.V., et al. Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. AIDS 17 (2003) 887-893
37. Tyndall M.W., Kerr T., Zhang R., King E., Montaner J.G., and Wood E. Attendance, drug use patterns, and referrals made from North America's first supervised injection facility. Drug and Alcohol Dependence (2005)
38. Vlahov D., Galai N., Safaeian M., Galea S., Kirk G.D., Lucas G.M., et al. Effectiveness of highly active anti-retroviral therapy among injection drug users with late-stage human immunodeficiency virus infection. American Journal of Epidemiology 161 (2005) 999-1012
39. Wohl A.R., Garland W.H., Valencia R., Squires K., Witt M.D., Kovacs A., et al. A randomized trial of directly administered anti-retroviral therapy and adherence case management intervention. Clinical Infectious Diseases 42 (2006) 1619-1627
40. Wood E., Hogg R.S., Yip B., Dong W.W., Wynhoven B., Mo T., et al. Rates of anti-retroviral resistance among HIV-infected patients with and without a history of injection drug use. AIDS 19 (2005) 1189-1195
41. Wood E., Hogg R.S., Yip B., Moore D., Harrigan P.R., and Montaner J.S. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl. AIDS 20 (2006) 1117-1123
42. Wood E., Kerr T., Palepu A., Zhang R., Strathdee S.A., Tyndall M.W., et al. Slower uptake of HIV anti-retroviral therapy among Aboriginal injection drug users. The Journal of Infection 52 (2006) 233-236
43. Wood E., Montaner J.S., Tyndall M.W., Schechter M.T., O'Shaughnessy M.V., and Hogg R.S. Prevalence and correlates of untreated human immunodeficiency virus type 1 infection among persons who have died in the era of modern anti-retroviral therapy. The Journal of Infectious Diseases 188 (2003) 1164-1170
44. Wood E., Montaner J.S., Yip B., Tyndall M.W., Schechter M.T., O'Shaughnessy M.V., et al. Adherence and plasma HIV RNA responses to highly active anti-retroviral therapy among HIV-1 infected injection drug users. CMAJ 169 (2003) 656-661
45. Wood E., Montaner J.S., Yip B., Tyndall M.W., Schechter M.T., O'Shaughnessy M.V., et al. Adherence to anti-retroviral therapy and CD4 T-cell count responses among HIV-infected injection drug users. Antiviral Therapy 9 (2004) 229-235